[Multicenter study of a slow-release theophylline: armophylline].
In a co-operative study involving 10 centres, 95 asthmatic patients were treated with Armophylline, a new slow-release theophylline for a period of 1 to 3 months. Eighty per cent of the patients receiving the drug in doses of 11 to 15 mg/kg/day immediately had adequate blood theophylline levels (7-20 mcg/ml). There was a significant decrease in dyspnoea and number of asthmatic attacks and a significant increase in FEV1 and FEV1/VC ratio. The drug was usually well tolerated. Side-effects, such as insomnia, headache or digestive disorders were, as a rule, mild.
D001249:Asthma / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D012129:Respiratory Function Tests; D013806:Theophylline / Q000097:blood / Q000627:therapeutic use*
D003692:Delayed-Action Preparations; D013806:Theophylline
Etude multicentrique d'une théophylline à libération progressive: armophylline.